Clinical and Observational Trials
-
Principal Investigator:
S. Zev Williams, MD, PhD
Researchers at Columbia are looking at the changes that happen in the placenta when people become pregnant. Participation in this study involves a blood draw at three time points. Participants will be paid $50 at each time point. Participants who complete all three time points will receive bonus compensation.
-
Principal Investigator:
S. Zev Williams, MD, PhD
Researchers at Columbia are looking at the changes that happen in the placenta when people become pregnant. Participation in this study involves a blood draw at three time points. Participants will be paid $50 at each time point. Participants who complete all three time points will receive bonus compensation.
-
Principal Investigator:
Uma M. Reddy, MD, MPH
This study will enroll participants who did or did not receive a SARS-CoV-2 vaccine during their pregnancy and have a child who is now 18-30 months of age. In order to assess the long-term outcomes of the offspring of those who received SARS-CoV-2 vaccine in pregnancy, a cohort study examining child developmental outcomes is needed. There are a number of known tests of developmental milestones that are easy to administer and can be administered remotely.
-
Principal Investigator:
June Y. Hou, MD
In this research study, an investigational medication named ACR-368 (also known as prexasertib) is being tested for the treatment of ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma. In this study, ACR-368 is being tested when it is given alone (called monotherapy) and when it is combined with low doses of a chemotherapy medication named gemcitabine (called combination therapy). ACR-368 has not been approved for use as a treatment for any condition, by government agencies in any country. ACR-368 is a type of medication called a checkpoint kinase inhibitor which may...
-
Principal Investigator:
June Y. Hou, MD
The main purpose of this study is to learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer.
-
Principal Investigator:
June Y. Hou, MD
The purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself or in combination with pembrolizumab, SOC chemotherapy, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of cancer cells. The study drugs, TransCon TLR7/8 Agonist and TransCon IL-2 /, have not been approved to be used by the Food and Drug Administration FDA for this study population. TransCon IL-2 / and TransCon TLR7/8 Agonist whereas designed...
Pages